The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy
Description
CONCLUSION: The humoral immune response to two doses of the SARS-CoV-2 BNT 162B2 vaccine in PKTRs without subsequent COVID-19 infection is suboptimal compared to that in hemodialysis recipients and in PKTRs with hybrid immunity from both infection
